Form D · Biotechnology
Latigo Biotherapeutics, Inc.
Thousand Oaks, CA · CIK 0002056611
Offering snapshot reported Feb 13, 2025 · SEC filing
- Reported sold
- $50M Offering amount: $150M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 28, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 13, 2025 | Initial | $49,999,995 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-538236
Source: Form D, filed Feb 13, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nima Farzan | Director, Executive |
| Tim Lugo | Executive |
| Deborah Palestrant | Director |
| Kevin Raidy | Director |
| Beth Seidenberg | Director |
| Nancy Stagliano | Director |
| Jim Tananbaum | Director |
| Tim Walbert | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1300 Rancho Conejo Blvd. Suite 305
Thousand Oaks, CA, 91320
Thousand Oaks, CA, 91320